Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baidu Inc (BIDU) vs Gilead Sciences, Inc. (GILD) Price & Performance

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Baidu Inc vs Gilead Sciences, Inc. — how do they compare? Baidu Inc trades at $103.74 (market cap $36.18B), while Gilead Sciences, Inc. trades at $136.96 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× Baidu Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.

BIDUGILD
Market Cap
$36.18B$168.35B
Sector
MediaHealth
52-Week High
$162.52$155.80
52-Week Low
$86.76$110.56
Enterprise Value
$32.81B$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baidu Inc

Baidu (BIDU) trades at $103.7, down 5.3% in the last session, reflecting bearish technical signals and recent earnings volatility. The stock shows weak profitability with a net margin of 1.02% and elevated P/E of 78.19, though it trades below book value. Recent news highlights autonomous vehicle testing in London and an upcoming Q2 2026 earnings report on August 18, 2026 (PRNewsWire, 2026-07-31).

Outlook is mixed: strong analyst buy consensus (75.47%) and a $169.80 price target suggest upside, but declining revenue, negative cash flows, and China market risks pose headwinds. AI initiatives offer growth potential, but investors face execution and macroeconomic uncertainties.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baidu Inc

Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.

Read more on BIDU

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD